Suppliers and packagers for generic pharmaceutical drug: mercaptopurine

mercaptopurine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	MERCAPTOPURINE	mercaptopurine	SUSPENSION;ORAL	216418	ANDA	Hikma Pharmaceuticals USA Inc.	0054-0879-49	1 BOTTLE, GLASS in 1 CARTON (0054-0879-49) / 100 mL in 1 BOTTLE, GLASS	2025-06-16
Hikma	MERCAPTOPURINE	mercaptopurine	SUSPENSION;ORAL	216418	ANDA	Hikma Pharmaceuticals USA Inc.	0054-4582-49	1 BOTTLE, GLASS in 1 CARTON (0054-4582-49) / 100 mL in 1 BOTTLE, GLASS	2025-02-26
Nova Labs Ltd	PURIXAN	mercaptopurine	SUSPENSION;ORAL	205919	NDA	Nova Laboratories, Ltd	62484-0020-2	1 BOTTLE in 1 CARTON (62484-0020-2) / 100 mL in 1 BOTTLE (62484-0020-1)	2014-04-28

Mercaptopurine Drug Substance Suppliers: Market Landscape and Key Manufacturers

Last updated: February 19, 2026

This report analyzes the global supplier landscape for mercaptopurine drug substance, identifying key manufacturers, their manufacturing capabilities, and regulatory standing. The market is characterized by a limited number of established producers with strong regulatory compliance, serving both generic and branded pharmaceutical sectors.

Who are the Primary Manufacturers of Mercaptopurine Drug Substance?

The production of mercaptopurine drug substance is concentrated among a select group of chemical manufacturers. These companies typically possess specialized expertise in complex organic synthesis and adhere to stringent Good Manufacturing Practices (GMP). Key players include:

• Cipla Limited: An Indian multinational pharmaceutical company with significant API manufacturing capabilities. Cipla produces mercaptopurine in bulk for global markets and holds numerous regulatory filings.
• Sun Pharmaceutical Industries Ltd.: Another leading Indian pharmaceutical firm, Sun Pharma is a major supplier of APIs, including mercaptopurine. The company operates multiple GMP-certified manufacturing facilities.
• Teanchem Co., Ltd.: A Taiwanese chemical manufacturer specializing in pharmaceutical intermediates and APIs. Teanchem has a demonstrated history of producing mercaptopurine.
• Symbiotec Pharmalab Private Limited: An Indian API manufacturer that produces a range of oncology drugs and intermediates. Symbiotec is a recognized supplier of mercaptopurine.
• Piramal Pharma Solutions: A global contract development and manufacturing organization (CDMO) with API development and manufacturing services. Piramal offers mercaptopurine synthesis and supply.

This group represents a substantial portion of the global supply chain for mercaptopurine API. Their consistent production and regulatory approvals are critical for ensuring the availability of this essential medication.

What are the Key Manufacturing Capabilities and Technologies Employed?

The synthesis of mercaptopurine involves multi-step organic chemical processes. Manufacturers must demonstrate proficiency in:

• Chiral Synthesis: While mercaptopurine itself is not chiral, the synthesis of related thiopurines or the control of specific impurities may require chiral handling techniques or analytical methods.
• Purification Techniques: High levels of purity are paramount for APIs. Manufacturers utilize techniques such as recrystallization, chromatography, and filtration to achieve required specifications.
• Process Validation: Robust process validation is a regulatory requirement. Manufacturers must demonstrate that their production processes consistently yield mercaptopurine meeting predefined quality attributes. This includes validation of critical process parameters and cleaning procedures.
• Scale-Up Expertise: The ability to scale production from laboratory to commercial volumes is essential. This requires deep understanding of reaction kinetics, heat transfer, and mass transfer to maintain yield and purity at larger scales.
• Analytical Method Development and Validation: Comprehensive analytical testing is required at various stages of production. Manufacturers develop and validate methods for assay, purity, related substances, residual solvents, and heavy metals. Common techniques include High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and spectroscopy (UV-Vis, IR, NMR).

Table 1 outlines common synthetic steps and associated challenges in mercaptopurine API manufacturing:

Synthetic Step	Key Reagents/Conditions	Potential Challenges
Thiolation/Sulfurylation	Sodium hydrosulfide, thiourea, carbon disulfide	Handling of hazardous sulfur compounds, by-product formation
Ring Closure	Formamide, other cyclizing agents	Achieving regioselectivity, high temperatures
Purification	Solvents, crystallization techniques	Solvent selection, polymorphic control, impurity removal
Drying and Milling	Vacuum ovens, milling equipment	Particle size distribution, moisture content

What is the Regulatory Standing and Compliance Landscape for Mercaptopurine Suppliers?

Regulatory compliance is a non-negotiable aspect of API manufacturing. Mercaptopurine suppliers must meet the requirements of major regulatory bodies worldwide. Key aspects include:

• Good Manufacturing Practices (GMP): All commercial API manufacturing must occur in GMP-compliant facilities. This includes adherence to guidelines from the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Manufacturers typically submit DMFs (in the US) or ASMFs (in Europe) to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, and facilities. Pharmaceutical companies reference these filings in their drug product applications.
• Inspections and Audits: Regulatory agencies conduct periodic inspections of manufacturing facilities. Furthermore, pharmaceutical companies conduct their own audits of API suppliers to ensure quality and compliance.
• ICH Guidelines: Compliance with International Council for Harmonisation (ICH) guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), is standard.
• Pharmacopoeial Standards: Mercaptopurine must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

Table 2 lists regulatory filings and inspections relevant to mercaptopurine suppliers:

Regulatory Authority	Filing Type	Purpose
US FDA	Drug Master File (DMF)	Provides confidential manufacturing details for review
EMA	Active Substance Master File (ASMF)	Facilitates review of API manufacturing by authorities
Various National	GMP Certificates	Evidence of compliance with national GMP standards
WHO	GMP Compliance	For supply to countries recognizing WHO GMP

Manufacturers with a history of successful regulatory inspections and a robust DMF/ASMF portfolio are preferred partners.

What is the Competitive Landscape and Market Dynamics?

The market for mercaptopurine API is relatively stable, driven by demand for both new formulations and established generic products. Key dynamics include:

• Generic Competition: As a long-established drug, mercaptopurine is widely available as a generic. This necessitates cost-effective manufacturing for API suppliers to remain competitive.
• Supply Chain Resilience: Pharmaceutical companies prioritize suppliers with demonstrated supply chain reliability, including redundancy in manufacturing or sourcing of critical raw materials.
• Quality and Regulatory Excellence: Suppliers with impeccable quality records and strong regulatory support are favored, especially for novel drug development or sensitive markets.
• Geographic Concentration: A significant portion of API manufacturing, including mercaptopurine, is concentrated in India and, to a lesser extent, China and Taiwan, due to cost advantages and established infrastructure.
• Consolidation: While not a major trend currently, consolidation among API manufacturers can occur, impacting the supply landscape.

The primary end-users of mercaptopurine API are pharmaceutical companies that formulate the drug substance into finished dosage forms (tablets, oral solutions). These include both originator companies with branded mercaptopurine products and generic drug manufacturers.

What are the Key Raw Materials and Supply Chain Considerations?

The synthesis of mercaptopurine relies on a specific set of chemical intermediates. Sourcing these raw materials reliably and at competitive prices is crucial for API manufacturers. Key considerations include:

• Precursor Chemicals: The synthesis typically starts from relatively common organic building blocks, which are then elaborated through a series of reactions. Specific precursors can include uracil derivatives, thiourea, and various sulfurizing agents.
• Supplier Qualification: API manufacturers must qualify their raw material suppliers to ensure consistent quality and prevent contamination. This involves audits, testing of incoming materials, and establishing clear specifications.
• Geopolitical Risks: The sourcing of some raw materials may be concentrated in specific geographic regions, introducing potential supply chain disruptions due to geopolitical events, trade disputes, or natural disasters.
• Regulatory Status of Intermediates: Certain intermediates may themselves be subject to regulatory oversight or controlled substance regulations in different jurisdictions, impacting their availability and transportation.
• Cost Volatility: The cost of raw materials can fluctuate based on global supply and demand, energy prices, and geopolitical factors. Manufacturers must manage this volatility through strategic sourcing and inventory management.

A robust supply chain strategy for mercaptopurine API involves not only manufacturing excellence but also a secure and diversified sourcing network for all critical raw materials.

What are the Future Outlook and Emerging Trends?

The future market for mercaptopurine API is likely to be shaped by several factors:

• Continued Generic Demand: The established therapeutic use of mercaptopurine in leukemia and inflammatory bowel disease ensures continued demand for generic formulations.
• Focus on Purity and Impurity Profiling: Regulatory agencies are increasingly scrutinizing API purity and the control of genotoxic impurities. Suppliers will need to invest in advanced analytical capabilities and process controls to meet these evolving standards.
• Supply Chain Modernization: Pharmaceutical companies are seeking greater transparency and resilience in their supply chains. This may lead to increased adoption of digital technologies for supply chain management and risk assessment.
• Sustainable Manufacturing Practices: Growing emphasis on environmental sustainability may drive demand for API manufacturers who adopt greener synthesis routes and reduce waste.
• Geographic Diversification: While India remains a dominant supplier, there may be a trend towards diversifying manufacturing footprints to mitigate geopolitical risks, potentially benefiting manufacturers in other regions.

The competitive landscape will likely continue to favor suppliers who demonstrate a commitment to quality, regulatory compliance, supply chain security, and cost-effectiveness.

Key Takeaways

• The mercaptopurine drug substance market is served by a limited number of established API manufacturers, primarily located in India.
• Key suppliers include Cipla Limited, Sun Pharmaceutical Industries Ltd., Teanchem Co., Ltd., Symbiotec Pharmalab Private Limited, and Piramal Pharma Solutions.
• Manufacturing requires specialized organic synthesis expertise, robust purification techniques, and strict adherence to GMP standards.
• Regulatory compliance, evidenced by DMFs/ASMFs and successful inspections, is a critical differentiator for suppliers.
• The market is driven by stable generic demand, with an increasing focus on supply chain resilience, quality, and impurity control.

FAQs

1. What is the primary therapeutic indication for mercaptopurine? Mercaptopurine is primarily used in the treatment of acute lymphoblastic leukemia (ALL) and, in some cases, Crohn's disease and ulcerative colitis.

2. Are there any significant new therapeutic applications emerging for mercaptopurine? While mercaptopurine is an established drug, research continues into its mechanisms of action and potential synergistic effects with other therapies, but no major new primary indications have emerged recently.

3. What are the typical shelf-life requirements for mercaptopurine drug substance? Shelf-life requirements for mercaptopurine drug substance are determined by stability studies and are typically specified in the Drug Master File, often ranging from 2 to 5 years when stored under controlled conditions.

4. How does the cost of mercaptopurine API compare to other thiopurine analogs like azathioprine? The cost of mercaptopurine API is generally comparable to azathioprine, though specific pricing depends on the supplier, volume, and purity specifications. Both are considered relatively cost-effective APIs due to their long history and generic availability.

5. What are the main challenges in ensuring the quality of mercaptopurine API from different suppliers? Key quality challenges include controlling specific process-related impurities, ensuring consistent polymorphic form, managing residual solvent levels, and verifying that the API meets all pharmacopoeial monograph requirements consistently across batches and suppliers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMFs). Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. [4] United States Pharmacopeial Convention. (n.d.). USP-NF. Retrieved from [USP Website] [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Ph. Eur. Monographs. Retrieved from [EDQM Website]